Page last updated: 2024-11-02

pioglitazone and Coronary Restenosis

pioglitazone has been researched along with Coronary Restenosis in 21 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.

Research Excerpts

ExcerptRelevanceReference
"Treatment of pioglitazone reduced neointimal hyperplasia in patients with STEMI treated with primary stent implantation without placing the patient at increased risk of complications."9.14Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. ( Domae, H; Kaneda, H; Matsumi, J; Minami, Y; Miyashita, Y; Mizuno, S; Saito, S; Shiono, T; Sugitatsu, K; Takahashi, S; Taketani, Y, 2009)
"This study investigates whether pioglitazone reduces neointimal hyperplasia after coronary stenting in nondiabetic patients with metabolic syndrome (MS) using intravascular ultrasound (IVUS)."9.12Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. ( Katayama, T; Kawakami, M; Kubo, N; Kuroki, M; Momomura, S; Saito, M; Tsuboi, K; Ueba, H; Yasu, T, 2007)
"The study population included 121 DM patients with coronary artery disease and they were randomly assigned to 60 patients taking 15 mg of pioglitazone daily in addition to their diabetic medications and 61 patients with placebo after the index procedure with drug-eluting stents (DESs)."5.17Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation. ( Cha, KS; Choi, JH; Hong, TJ; Kim, BW; Kim, SP; Lee, HC; Lee, HW; Oh, JH; Park, JH; Park, JS; Song, S; Yang, MJ, 2013)
"Treatment of pioglitazone reduced neointimal hyperplasia in patients with STEMI treated with primary stent implantation without placing the patient at increased risk of complications."5.14Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. ( Domae, H; Kaneda, H; Matsumi, J; Minami, Y; Miyashita, Y; Mizuno, S; Saito, S; Shiono, T; Sugitatsu, K; Takahashi, S; Taketani, Y, 2009)
"This study investigates whether pioglitazone reduces neointimal hyperplasia after coronary stenting in nondiabetic patients with metabolic syndrome (MS) using intravascular ultrasound (IVUS)."5.12Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. ( Katayama, T; Kawakami, M; Kubo, N; Kuroki, M; Momomura, S; Saito, M; Tsuboi, K; Ueba, H; Yasu, T, 2007)
" Pioglitazone has antiatherogenic property through the inhibition of inflammation."3.74Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. ( Daida, H; Ikeda, E; Kajimoto, K; Kasai, T; Kubota, N; Miyauchi, K; Sumiyoshi, K; Yokoyama, T, 2008)
"Pioglitazone treatment might suppress in-stent neointimal proliferation and reduce incidence of TLR after PCI in patients with T2DM."2.74A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). ( Fitzgerald, PJ; Honda, Y; Ikeno, F; Ito, A; Kataoka, T; Kobayashi, Y; Okura, H; Sakanoue, Y; Shimeno, K; Taguchi, H; Takagi, T; Tamita, K; Toda, I; Waseda, K; Yamamuro, A; Yamasaki, M; Yanagi, S; Yoshikawa, J; Yoshiyama, M, 2009)
"The treatment with pioglitazone in type 2 diabetic patients significantly reduced leptin."2.72A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. ( Fukui, T; Itoh, S; Katagiri, T; Kawamura, K; Konno, N; Kusuyama, T; Nishio, K; Sakurai, M; Shigemitsu, M, 2006)
"Pioglitazone treatment seems to have more beneficial effects than rosiglitazone and no significantly increased cardiovascular risk was detected for both agents."2.55Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials. ( Chen, S; Dai, J; Hua, J; Mao, W; Qiu, Y; Xu, X; Zhou, X; Zhu, M, 2017)
"The treatment of pioglitazone was associated with a reduction in ISR and TLR in T2DM patients suffering from PCI, except the incidence of MACE."2.53Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis. ( Chen, L; Qi, GX; Shi, LY; Tian, W; Zhao, SJ; Zhong, ZS, 2016)
"The prevalence of type 2 diabetes mellitus (T2DM) is growing at an alarming rate and reaching epidemic proportions, and cardiovascular disease continues to be one of the leading causes of death in the United States."2.44PPARgamma agonists and coronary atherosclerosis. ( Chilton, R; Sulistio, MS; Thukral, N; Zion, A, 2008)
"Insulin resistance is central to the pathogenesis of type 2 diabetes and may contribute to atherogenesis, either directly or through associated risk factors."2.42Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. ( Evans, M; Rees, A; Roberts, AW; Thomas, A, 2003)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (66.67)29.6817
2010's7 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhou, X1
Chen, S1
Zhu, M1
Hua, J1
Dai, J1
Xu, X1
Qiu, Y1
Mao, W1
Lee, HW1
Lee, HC1
Kim, BW1
Yang, MJ1
Park, JS1
Oh, JH1
Choi, JH1
Cha, KS1
Hong, TJ1
Kim, SP1
Song, S1
Park, JH2
Zhang, MD1
Zhang, YH1
Zhu, EJ1
Qiao, SB1
Lv, SZ1
Zhao, QM1
Zhao, SJ1
Zhong, ZS1
Qi, GX1
Shi, LY1
Chen, L1
Tian, W1
Kaneda, H1
Shiono, T1
Miyashita, Y1
Takahashi, S1
Taketani, Y1
Domae, H1
Matsumi, J1
Mizuno, S1
Minami, Y1
Sugitatsu, K1
Saito, S1
Takagi, T2
Okura, H1
Kobayashi, Y1
Kataoka, T1
Taguchi, H1
Toda, I1
Tamita, K2
Yamamuro, A2
Sakanoue, Y1
Ito, A1
Yanagi, S1
Shimeno, K1
Waseda, K1
Yamasaki, M1
Fitzgerald, PJ1
Ikeno, F1
Honda, Y1
Yoshiyama, M1
Yoshikawa, J2
Nissen, SE1
Hong, SJ1
Kim, ST1
Kim, TJ1
Kim, EO1
Ahn, CM1
Kim, JS1
Lee, KM1
Lim, DS1
Patel, D1
Walitt, B1
Lindsay, J1
Wilensky, RL1
Yokoi, H1
Yamabe, K1
Katayama, M1
Mizoguchi, S1
Ibuki, M1
Tani, T1
Tanabe, K1
Nagai, K1
Shiratori, K1
Morioka, S1
Roberts, AW1
Thomas, A1
Rees, A1
Evans, M1
Marx, N1
Wöhrle, J1
Nusser, T1
Walcher, D1
Rinker, A1
Hombach, V1
Koenig, W1
Höher, M1
Schömig, A1
Kastrati, A1
Wessely, R1
Nishio, K1
Sakurai, M1
Kusuyama, T1
Shigemitsu, M1
Fukui, T1
Kawamura, K1
Itoh, S1
Konno, N1
Katagiri, T1
Joner, M1
Farb, A1
Cheng, Q1
Finn, AV1
Acampado, E1
Burke, AP1
Skorija, K1
Creighton, W1
Kolodgie, FD1
Gold, HK1
Virmani, R1
Katayama, T1
Ueba, H1
Tsuboi, K1
Kubo, N1
Yasu, T1
Kuroki, M1
Saito, M1
Momomura, S1
Kawakami, M1
Douglas, JS1
Kasai, T1
Miyauchi, K1
Yokoyama, T1
Kajimoto, K1
Sumiyoshi, K1
Kubota, N1
Ikeda, E1
Daida, H1
Sulistio, MS1
Zion, A1
Thukral, N1
Chilton, R1

Reviews

8 reviews available for pioglitazone and Coronary Restenosis

ArticleYear
Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials.
    Scientific reports, 2017, 10-31, Volume: 7, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Restenosis;

2017
Effect of pioglitazone on in-stent restenosis after coronary drug-eluting stent implantation: a meta-analysis of randomized controlled trials.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Humans; Hypoglycemic Agents; Piog

2014
Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis.
    PloS one, 2016, Volume: 11, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Occlusion; Coronary Restenosis;

2016
Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis.
    JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Angiography; Coronary Resten

2011
[Pioglitazone].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 7

    Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Diabetes Complications; Humans; Hypoglycemic Ag

2011
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
    Current opinion in lipidology, 2003, Volume: 14, Issue:6

    Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Resten

2003
Pharmacologic approaches to restenosis prevention.
    The American journal of cardiology, 2007, Sep-03, Volume: 100, Issue:5A

    Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease

2007
PPARgamma agonists and coronary atherosclerosis.
    Current atherosclerosis reports, 2008, Volume: 10, Issue:2

    Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopath

2008

Trials

8 trials available for pioglitazone and Coronary Restenosis

ArticleYear
Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation.
    Yonsei medical journal, 2013, Volume: 54, Issue:6

    Topics: Aged; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Hypoglycemi

2013
Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:13

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis;

2009
A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Blood Glucose; California; Cell Proliferation; Coronary Angiog

2009
Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.
    Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Glucose; Cardiovascular Agents; Cell

2010
Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.
    American heart journal, 2003, Volume: 146, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Blood Glucose; Coronary Angiography; Coronary Disease; Coronar

2003
Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.
    Circulation, 2005, Nov-01, Volume: 112, Issue:18

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Coronary Disease; C

2005
A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.
    Diabetes care, 2006, Volume: 29, Issue:1

    Topics: Aged; Blood Pressure; Coronary Disease; Coronary Restenosis; Cytokines; Diabetes Mellitus, Type 2; D

2006
Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.
    American heart journal, 2007, Volume: 153, Issue:5

    Topics: Coronary Restenosis; Coronary Vessels; Female; Follow-Up Studies; Humans; Hyperplasia; Hypoglycemic

2007

Other Studies

5 other studies available for pioglitazone and Coronary Restenosis

ArticleYear
Pioglitazone to reduce restenosis after bare-metal stent placement?
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Cell Proliferation; Coronary Restenosis; Diabetes Mellitus, Type 2;

2009
[Timely intervention with insulin sensitizer. Controlling cardiovascular risks].
    MMW Fortschritte der Medizin, 2003, Jun-05, Volume: 145, Issue:23

    Topics: Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Thera

2003
Prevention of restenosis by systemic drug therapy: back to the future?
    Circulation, 2005, Nov-01, Volume: 112, Issue:18

    Topics: Cilostazol; Controlled Clinical Trials as Topic; Coronary Restenosis; Double-Blind Method; Drug Admi

2005
Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1.
    Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:1

    Topics: Administration, Oral; Animals; Atherosclerosis; Cell Proliferation; Cells, Cultured; Chemokine CCL2;

2007
Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting.
    Atherosclerosis, 2008, Volume: 197, Issue:2

    Topics: Animals; Chemokine CCL2; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Humans; Hypo

2008